Screening of Bufadienolides from Toad Venom Identifies Gammabufotalin as a Potential Anti-inflammatory Agent

Yuanru Zheng,Lijuan Deng,Huihui Cao,Nishan Xu,Dongmei Zhang,Haiyan Tian,Baojing Li,Zibin Lu,Wencai Ye,Linzhong Yu,Chunlin Fan,Junshan Liu
DOI: https://doi.org/10.1055/a-1248-2626
IF: 3.007
2022-01-01
Planta Medica
Abstract:Toad venom ( Chansu ) is used in the treatment of infectious and inflammatory diseases in China and East/Southeast Asian countries. However, the anti-inflammatory components of toad venom have not yet been systematically evaluated and clearly defined. To investigate the anti-inflammatory effects of toad venom and identify new anti-inflammatory ingredients, we used zebrafish, an alternative drug screening model, to evaluate the anti-inflammatory effects of 14 bufadienolides previously isolated from toad venom. Most of the bufadienolides were found to exert significant anti-inflammatory effects on lipopolysaccharide-, CuSO (4) -, or tail transection-induced zebrafish inflammatory models. Moreover, gammabufotalin ( 6 ) inhibits lipopolysaccharide-induced inflammation by suppressing the myeloid differentiation primary response 88/nuclear factor-kappa B and STAT3 signal pathways. This study confirms the potential of zebrafish in drug screening, clarifies the anti-inflammatory effects of bufadienolides from toad venom, and indicates that gammabufotalin may be developed as a novel therapeutic agent for inflammatory diseases in the future.
What problem does this paper attempt to address?